FOXMEYER FY 1994 SALES UP 12.6% TO $5.1 BIL.; NET INCOME TOTALS $26.9 MIL.: BINDLEY WESTERN SEES IMPROVEMENT IN FORWARD BUYING OPPORTUNITIES IN 1994
FoxMeyer sales rose 12.6% to $5.1 bil. in the fiscal year ended March 31, the company reported May 11. Net income for the Dallas-based wholesaler reached $26.9 mil., in contrast to the previous year when a $42.8 mil. third-quarter charge related to money owed by Phar-Mor depleted FoxMeyer earnings to $220,000. For the FY 1994 fourth quarter, sales were ahead by 1.8% to $1.3 bil. and earnings shot up 82.2% to $10.1 mil.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth